Kalaris Therapeutics (NASDAQ:KLRS) Raised to “Hold” at Wall Street Zen

Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

Several other brokerages have also commented on KLRS. Chardan Capital began coverage on shares of Kalaris Therapeutics in a research report on Tuesday, December 23rd. They set a “buy” rating and a $19.00 target price on the stock. Citigroup reiterated an “outperform” rating on shares of Kalaris Therapeutics in a report on Thursday, December 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kalaris Therapeutics in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $14.00.

Kalaris Therapeutics Price Performance

Shares of KLRS stock opened at $8.67 on Friday. The business’s fifty day moving average price is $9.44 and its 200 day moving average price is $7.18. Kalaris Therapeutics has a 1-year low of $2.14 and a 1-year high of $12.90. The firm has a market capitalization of $162.13 million, a PE ratio of -2.30 and a beta of -0.13.

Insiders Place Their Bets

In other news, Director Srinivas Akkaraju acquired 479,847 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The stock was purchased at an average cost of $10.42 per share, with a total value of $5,000,005.74. Following the purchase, the director directly owned 1,979,847 shares of the company’s stock, valued at approximately $20,630,005.74. This trade represents a 31.99% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. 74.99% of the stock is owned by insiders.

Institutional Trading of Kalaris Therapeutics

Several large investors have recently bought and sold shares of KLRS. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Kalaris Therapeutics in the fourth quarter valued at $34,000. Barclays PLC purchased a new stake in shares of Kalaris Therapeutics in the 4th quarter worth about $51,000. Johnson Financial Group Inc. purchased a new stake in shares of Kalaris Therapeutics in the 3rd quarter worth about $58,000. Keel Point LLC acquired a new stake in Kalaris Therapeutics in the 4th quarter valued at about $86,000. Finally, XTX Topco Ltd acquired a new stake in Kalaris Therapeutics in the 4th quarter valued at about $92,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.